SCHEDULE: Vanguard Boosts Dexcom Stake to 12.61%

The Vanguard Group reported a significant beneficial ownership stake of 12.61% in Dexcom Inc., holding 49.46 million shares as of September 30, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 49,455,578 shares of Dexcom Inc. common stock.
• This represents 12.61% of Dexcom Inc.'s outstanding common stock.
• Vanguard holds sole dispositive power over 45,667,627 shares and shared dispositive power over 3,787,951 shares.
• Vanguard holds shared voting power over 2,366,864 shares and no sole voting power.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Dexcom Inc.

Sentiment

Score: 7

Explanation: A large, passive institutional investment by The Vanguard Group, representing over 12% of the company, is generally viewed positively as it indicates strong institutional confidence and a long-term holding strategy, without implying any intent to influence control.

Positives

• The Vanguard Group, a major institutional investor, holds a significant 12.61% stake in Dexcom Inc., indicating strong institutional confidence in the company.
• Vanguard's substantial holding suggests a long-term investment perspective, as indicated by the certification that shares are held in the ordinary course of business.

Negatives

• No specific negative information regarding Dexcom Inc. is disclosed in this beneficial ownership filing.

Risks

• No specific risks related to Dexcom Inc.'s operations or financial health are detailed in this beneficial ownership report.
• General market risks associated with large institutional holdings, such as potential future sales impacting share price, are inherent but not explicitly detailed as risks by the filing itself.

Future Outlook

NA

Industry Context

The significant stake held by The Vanguard Group in Dexcom Inc. underscores the continued institutional interest in the medical device sector, particularly companies focused on diabetes management technology. Large institutional holdings like this often signal confidence in a company's market position, growth prospects, and long-term value within its industry.

Stakeholder Impact

• Shareholders: The significant institutional ownership by Vanguard may provide a sense of stability and validation for existing shareholders, potentially attracting further institutional interest.
• Management: A large, passive institutional holder like Vanguard typically monitors corporate performance but does not actively seek to influence day-to-day management or strategic decisions, as certified in the filing.

Key Dates

Recommendation

The filing indicates a substantial, passive institutional holding by The Vanguard Group, which is generally a positive signal of long-term confidence in Dexcom Inc. However, this filing alone does not provide new operational or financial performance data to warrant a 'buy' or 'sell' recommendation. It primarily confirms a significant existing institutional position, suggesting a 'hold' is appropriate for investors awaiting further fundamental updates.

Keywords

Dexcom Inc, Vanguard Group, DXCM, Schedule 13G, beneficial ownership, institutional investment, common stock, medical devices, diabetes care